We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

55 hedge funds and large institutions have $127M invested in Avalo Therapeutics in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

58% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 12

43% more capital invested

Capital invested by funds: $88.5M → $127M (+$38.5M)

28% more funds holding

Funds holding: 43 → 55 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

Holders
55
Holders Change
+12
Holders Change %
+27.91%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
19
Reduced
12
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$14.3M
2
AC
Armistice Capital
New York
+$4.42M
3
OM
Opaleye Management
Massachusetts
+$2.95M
4
SCM
Sio Capital Management
New York
+$2.52M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.58M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$407K
2
State of Tennessee, Department of Treasury
State of Tennessee, Department of Treasury
Tennessee
-$64K
3
JP Morgan Chase
JP Morgan Chase
New York
-$50.8K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$48K
5
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$42K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$77.8M +$4.42M +609 +6%
NCM
2
Nantahala Capital Management
Connecticut
$14.8M +$14.3M +1,973 New
OM
3
Opaleye Management
Massachusetts
$8.77M +$2.95M +406 +53%
BlackRock
4
BlackRock
New York
$4.5M +$1.15M +158 +36%
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.78M +$1.58M +217 +76%
BFM
6
Boothbay Fund Management
New York
$3.09M +$697K +96 +30%
SCM
7
Sio Capital Management
New York
$2.6M +$2.52M +347 New
Renaissance Technologies
8
Renaissance Technologies
New York
$1.26M +$1.22M +168 New
SCM
9
Stonepine Capital Management
Oregon
$1.17M +$1.13M +156 New
IC
10
Ikarian Capital
Texas
$1.05M -$407K -56 -29%
State Street
11
State Street
Massachusetts
$1.02M -$7.26K -1 -0.7%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$957K +$261K +36 +39%
Northern Trust
13
Northern Trust
Illinois
$920K +$181K +25 +26%
DCM
14
DAFNA Capital Management
California
$827K +$799K +110 New
Two Sigma Investments
15
Two Sigma Investments
New York
$672K +$653K +90 New
Millennium Management
16
Millennium Management
New York
$413K +$225K +31 +129%
N
17
Nuveen
North Carolina
$402K +$211K +29 +116%
Goldman Sachs
18
Goldman Sachs
New York
$378K +$370K +51 New
Los Angeles Capital Management
19
Los Angeles Capital Management
California
$335K +$283K +39 +650%
Assenagon Asset Management
20
Assenagon Asset Management
Luxembourg
$300K +$290K +40 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$196K +$43.6K +6 +30%
Invesco
22
Invesco
Georgia
$188K +$29K +4 +19%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$179K +$174K +24 New
Charles Schwab
24
Charles Schwab
California
$176K +$29K +4 +21%
MWM
25
Minot Wealth Management
Massachusetts
$107K – – –
1
2 3

AVTX Hedge Fund Activity: Q2 2020 in Review

55 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2020, worth a combined $127M — up 43% from $88.5M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVTX positions and 4 closed out — a net gain of 12 holders — while 19 added to existing stakes and 12 trimmed.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Ikarian Capital, cutting an estimated $407K.

  • 55 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2020, up from 43 in Q1 2020.
  • Funds reported $127M of Avalo Therapeutics stock for Q2 2020, up 43% quarter-over-quarter.
  • 16 funds opened new Avalo Therapeutics positions in Q2 2020 and 4 closed out, a net change of +12 holders.
  • The largest Avalo Therapeutics buyer in Q2 2020 was Nantahala Capital Management, an estimated $14.3M added.
  • The largest Avalo Therapeutics seller in Q2 2020 was Ikarian Capital, an estimated $407K sold.

Based on aggregated 13F filings for Q2 2020.